Therapeutic efficacy of lenvatinib as third-line treatment after regorafenib for unresectable hepatocellular carcinoma progression.
Atsushi HiraokaTakashi KumadaTakeshi HatanakaToshifumi TadaKazuya KariyamaJoji TaniShinya FukunishiMasanori AtsukawaMasashi HirookaKunihiko TsujiToru IshikawaKoichi TakaguchiEi ItobayashiKazuto TajiriNoritomo ShimadaHiroshi ShibataHironori OchiKazuhito KawataSatoshi YasudaHidenori ToyodaOgawa ChikaraTsutomu TamaiSatoru KakizakiHiroki TojimaTamon NagashimaTakashi UenoDaichi TakizawaAtsushi NaganumaHideko OhamaKazuhiro NousoAkemi TsutsuiTakuya NaganoNorio ItokawaTomomi OkuboTaeang AraiMichitaka ImaiYohei KoizumiShinichiro NakamuraKouji JokoKojiro MichitakaYoichi HiasaMasatoshi Kudonull nullPublished in: Hepatology research : the official journal of the Japan Society of Hepatology (2021)
These results show that lenvatinib is a good sequential treatment option after progression under regorafenib therapy in unresectable hepatocellular carcinoma patients with better hepatic reserve function.